Invesco Biotechnology & Genome ETF
PBE
PBE
101 hedge funds and large institutions have $77.1M invested in Invesco Biotechnology & Genome ETF in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 22 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
18% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 22
Holders
101
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$3.88M | |
| 2 | +$2.19M | |
| 3 | +$1.54M | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$773K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$695K |
Top Sellers
| 1 | -$673K | |
| 2 | -$644K | |
| 3 | -$629K | |
| 4 |
Goldman Sachs
New York
|
-$503K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$231K |